News

Bonumose’s Low-Cost Tagatose Process Receives Key Health Agency Approvals; Construction of First Production Facility on Schedule for Spring 2022 Opening

ASR Group – exclusive sales and distribution partner – reports strong customer demand for the unique, rare sugar, accelerating the timeline for a second production plant.
Bonumose, Inc. announces the achievement of regulatory and food application milestones in the United States and Canada for the low-glycemic, rare sugar tagatose, as the company progresses on time and on schedule for the opening of its first commercial production facility in Spring 2022.
“A low-cost tagatose supply is highly sought after by leading, global food companies for a wide variety of applications that meet sugar-reduction targets in confectionery, ready-to-eat cereal, ice cream, yogurt, beverages, meal replacement drinks, cookies, bars and other popular categories,” said Ed Rogers, CEO of Bonumose. “Tagatose’s unique features enable it to meet calorie-reduction targets without compromising taste or texture while working within companies’ existing food production lines.”

Tagatose – a rare sugar that occurs in tiny quantities in some fruits and grains as well as in the cocoa tree – is 92% as sweet as sugar, maintains a clean, no-aftertaste flavor profile as well as provides critical functionality such as bulking, mouthfeel, caramelization, freezing-point depression and low hygroscopicity. Tagatose has a negligible glycemic index (3), 60 percent fewer calories than sucrose and prebiotic, fiber-like benefits by feeding healthy probiotics in the gut.

To date, the obstacle limiting widespread use of tagatose has been its high cost. Bonumose solves the issue through a lower-cost method using non-dairy, plant-based starch, enzymes and a streamlined process that eliminates several complicated steps that inflate the cost of tagatose and allulose for other producers.

The U.S. Food and Drug Administration (FDA) recently approved Bonumose’s unique method. Additionally, Health Canada approved Bonumose’s process, marking the first time tagatose has been approved for sale in Canada. Regulatory submissions are underway and planned in all major markets worldwide.

Bonumose will launch tagatose production and sales in the first half 2022 with ASR Group, the world’s largest cane sugar refiner and marketer. ASR Group is Bonumose’s exclusive distribution partner in the United States, Canada, Mexico and Western Europe. ASR Group’s customers have successfully tested tagatose in formulations to meet reduction targets without sacrificing taste or function.

“Tagatose has performed extremely well for our customers across a wide variety of applications, and they are enthusiastic about having an affordable supply of tagatose available to them soon,” said Jim Kappas, ASR Group’s Vice President of Specialty Ingredients. “Using these insights, we forecast demand may already outstrip the production capacity at Bonumose’s first production plant, and we will likely need to scale up as soon as possible.”

Recent News

06/29/2022

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by